Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Beats Expectations By $0.64 EPS

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64, Zacks reports.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $142.49 on Friday. The company’s 50-day moving average price is $132.19 and its two-hundred day moving average price is $132.29. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The stock has a market capitalization of $8.65 billion, a PE ratio of -17.63 and a beta of 0.64.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ASND shares. TD Cowen lowered their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a report on Thursday. UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a report on Thursday. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $193.43.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.